Is Mitochondrial+ blend legal in Australia?

A 55 mg three-peptide vial, sold at 9 mg SS-31, 16 mg TB-500 and 30 mg MOTS-c. MOTS-c is more than half the powder and has no human trial; the SS-31 component with an actual phase 3 programme is the smallest share at 16.4%; and the third component is a repair peptide with no mitochondrial rationale at all.

This vial is the clearest case in the batch of the arithmetic changing what the product is. The split is 9 mg SS-31, 16 mg TB-500 and 30 mg MOTS-c, 55 mg of powder.

Mechanism: SS-31 binds cardiolipin in the inner mitochondrial membrane and is described as stabilising it. MOTS-c is a mitochondrially encoded peptide described as activating AMPK.

Regulatory history: Not approved. None of the three components holds a marketing authorisation and no regulator has evaluated the combination.

Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.

The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for Mitochondrial+ blend at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.